Late breaking abstract L16 Dapirolizumab Pegol showed significant improvement in SLE disease activity in our Phase 3 tri

Late breaking abstract L16 Dapirolizumab Pegol showed significant improvement in SLE disease activity in our Phase 3 trial. Key findings: - 49.5% of patients achieved BICLA response at Week 48 vs 34.6% on placebo (p=0.0110). - 60.1% achieved SRI-4 response vs 41.1% on placebo… https://t.co/ZawdsLOxmK https://t.co/gpV3KayIW1